Immunohistochemistry-Based Fluorescent Nanoparticle Assay for Determination of Antibody Binding Capacity and Its Correlation with Flow Cytometry Analysis

被引:0
作者
Tatsumi, Atsuro [1 ,3 ]
Morichika, Keisuke [1 ]
Krueger, Joseph [2 ]
Yokota, Hiroyuki [1 ]
机构
[1] KONICA MINOLTA INC, Precis Med Business Unit, Healthcare Business Headquarters, Tokyo, Japan
[2] Invicro, Adv Pathol Serv, Needham, MA USA
[3] KONICA MINOLTA INC, Precis Med Business Unit, Healthcare Business Headquarters, 1 Sakuramachi, Hino, Tokyo 1918511, Japan
关键词
Antibody binding capacity; immunohistochemistry; flow cytometry; fluorescent nanoparticle; RECEPTOR OCCUPANCY;
D O I
10.1080/00032719.2022.2153365
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The determination of antibody binding capacity is crucial in the development of drug antibodies. Despite its widespread use, flow cytometry may only be used to evaluate single cells in solution. In addition, analyzing the antibody localization in tissue sections of animal models after drug administration, as in immunohistochemistry (IHC), is desirable. In this study, antibody-treated cells were fixed on glass slides, and their analysis was directly compared with flow cytometry. Cell-bound antibodies were quantitatively detected using a method that relies on phosphor-integrated dots (PIDs), which are highly brilliant nanoparticles applicable to immunohistochemistry. The outcomes of this approach were highly correlated with flow cytometry, suggesting that it is able to quantitatively detect cell-bound antibodies at a level comparable with flow cytometry. Therefore, this novel IHC-based technique is valuable for quantitative analysis and localization of antibodies in tissue sections of drug administration.
引用
收藏
页码:2053 / 2060
页数:8
相关论文
共 16 条
  • [11] Role of receptor occupancy assays by flow cytometry in drug development
    Stewart, Jennifer J.
    Green, Cherie L.
    Jones, Nicholas
    Liang, Meina
    Xu, Yuanxin
    Wilkins, Danice E. C.
    Moulard, Maxime
    Czechowska, Kamila
    Lanham, David
    McCloskey, Thomas W.
    Ferbas, John
    van der Strate, Barry. W. A.
    Hogerkorp, Carl-Magnus
    Wyant, Timothy
    Lackey, Alan
    Litwin, Virginia
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (02) : 110 - 116
  • [12] Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
    Suzuki, Mikiko
    Yagishita, Shigehiro
    Sugihara, Kiyoshi
    Ogitani, Yusuke
    Nishikawa, Tadaaki
    Ohuchi, Mayu
    Teishikata, Takashi
    Jikoh, Takahiro
    Yatabe, Yasushi
    Yonemori, Kan
    Tamura, Kenji
    Hasegawa, Kosei
    Hamada, Akinobu
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3970 - 3979
  • [13] One-step visualization of natural cell activities in non-labeled living spheroids
    Tanaka, Shotaro
    Takizawa, Kotaro
    Nakamura, Fumio
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [14] High-Sensitivity Immunohistochemistry Method Using a Combination of Fluorescent Nanoparticles and Tyramide Linker
    Tatsumi, Atsuro
    Morichika, Keisuke
    Krueger, Joseph
    Yokota, Hiroyuki
    [J]. ANALYTICAL LETTERS, 2023, 56 (07) : 1206 - 1215
  • [15] Detection of tumor marker CA125 in ovarian carcinoma using quantum dots
    Wang, HZ
    Wang, HY
    Liang, RQ
    Ruan, KC
    [J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2004, 36 (10) : 681 - 686
  • [16] Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
    Wuellner, Ulrich
    Klupsch, Kristina
    Buller, Fabian
    Attinger-Toller, Isabella
    Santimaria, Roger
    Zbinden, Irene
    Henne, Patricia
    Grabulovski, Dragan
    Bertschinger, Julian
    Brack, Simon
    [J]. ANTIBODIES, 2015, 4 (04) : 426 - 440